Close
Novotech
Jabsco PureFlo 21 Single Use

Kindeva Announces the Appointment of David Stevens as President

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...
- Advertisement -

Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to the newly created role of President. In this capacity, David will lead Kindeva’s global operations.

With over 20 years of experience in the CDMO industry, David has led high-performing teams across biologics, sterile, and drug-product manufacturing. His insight and customer-centric approach will guide Kindeva’s continued growth and success.

“It’s an honor to take on this role at such an exciting time for Kindeva,” said David Stevens, President of Kindeva. “I look forward to working closely with the Kindeva team and our customers to advance our mission and drive the next chapter of our growth story.”

“David has been a pivotal leader, driving Kindeva’s growth and commitment to customers over the past three years,” said Milton Boyer, CEO of Kindeva. “The elevation of David to the role of President reflects the continued evolution of Kindeva and will enable us to build on our strong momentum, enhance our strategic focus, and continue delivering for our partners and patients worldwide.”

Latest stories

Related stories

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »